难治性Graves病全甲状腺切除或放射性碘治疗后促甲状腺素受体抗体水平变化
该回顾性研究纳入130例因抗甲状腺药物难治性Graves病接受全甲状腺切除(TTx)或放射性碘(RAI)治疗的患者,比较两种治疗后促甲状腺素结合抑制免疫球蛋白(TBII)水平变化。TTx后TBII持续下降,RAI后先升后降;TTx组TBII降至4.5 IU以下的中位时间短于RAI组。
要点
- TTx后TBII持续下降,RAI后TBII先升高约138天再缓慢下降。
- TTx组TBII降至4.5 IU以下的中位时间318天,短于RAI组的659天。
- RAI组TBII>4.5 IU/L者6个月占82%、1年占67%、2年占3%。
核心结论
- 难治性Graves病患者接受TTx或RAI后TBII水平变化不同,TTx后下降更快。
- 选择TTx或RAI时应结合年龄、甲亢严重程度、甲状腺肿、眼病及未来妊娠计划考虑此差异。
主要发现
- TTx组TBII持续下降,RAI组TBII先升高(估计中位时间138天)后缓慢下降。
- TTx组TBII下降速度快于RAI组(p < 0.001)。
- TBII降至4.5 IU以下的中位时间:TTx组318天,RAI组659天。
- RAI组TBII>4.5 IU/L者:6个月70例(82%)、1年57例(67%)、2年3例(3%)。
- TTx组中年轻及基线TBII较低者下降更快;RAI组中甲状腺体积较小者下降更快。
关键数值与推荐
- 4.5 IU为3倍正常上限,已知为胎儿甲亢风险因素。
- RAI组TBII>4.5 IU/L者6个月占82%、1年占67%、2年占3%。
临床怎么用
- 对难治性Graves病选择TTx或RAI时,需考虑TBII下降速度差异及患者年龄、甲亢严重程度、甲状腺肿、眼病和未来妊娠计划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The actions of thyrotropin-binding inhibitory immunoglobulins (TBIIs) against thyrotropin receptors in thyroid follicular cells have been studied as important etiological factors in Graves' disease (GD). The purpose of this study was to investigate changes in the TBII levels of patients undergoing total thyroidectomy (TTx) or radioactive iodine (RAI) therapy for GD refractory to antithyroid drugs (ATDs). Methods: We enrolled patients who underwent TTx or RAI for GD with previous ATD use between January 2011 and December 2017 at the Samsung Medical Center in Seoul, Korea. Thorough retrospective reviews of medical records were performed in 130 patients. Results: Patients with goiter, ophthalmopathy, high levels of TBIIs, and high doses of ATDs received TTx. Elderly patients with arrhythmia received RAI. We observed that TBII levels continued to decrease after TTx. On the contrary, TBIIs initially increased for 138 days (estimated median time) and then decreased slowly after RAI. A faster decline in TBII levels was observed in the TTx group than in the RAI group (p < 0.001). The estimated median time for TBIIs to decrease below 4.5 IU (3 × upper normal limit, which is known to be a risk factor for fetal hyperthyroidism) was 318 days in the TTx group and 659 days in the RAI group, respectively. In the RAI group, high levels of TBII (>4.5 IU/L) were present in 70 (82%) at 6 months, 57 (67%) at 1 year, and 3 (3%) at 2 years. In the TTx group, rapid decreases in TBII levels were observed in younger patients and those with lower baseline TBII levels. In the RAI group, smaller thyroid volume was correlated with more rapid decrease in TBII levels. Conclusions: The changes in TBII levels following TTx or RAI were different in patients with refractory GD. When deciding on TTx or RAI, this difference should be considered with patient age, severity of hyperthyroidism, goiter, ophthalmopathy, and future pregnancy plans (for young female patients).
引用
- Kim J, Choi MS, Park J, et al. Changes in Thyrotropin Receptor Antibody Levels Following Total Thyroidectomy or Radioiodine Therapy in Patients with Refractory Graves' Disease. Thyroid. 2021. PMID: 33947272. doi:10.1089/thy.2020.0756
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。